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Objectives: With a vast number of possible treatment options for Multiple 
Myeloma patients, it is unclear in which combination and sequencing compounds 
should be used to achieve prolonged overall survival. This question cannot be timely 
answered with an RCT, a health economic model (1) was used to approximate for 
OS and adopted for a German cost setting. MethOds: Using a combination of 
meta-analysis and -regression, the possible overall survival of different therapy 
sequences is approximated in a Markov model. Data source for this model is a 
systematic literature research covering 2008-2012, identifying a total of 68 studies 
and 11.115 patients in Multiple Myeloma. From each study treatment arm, response 
per therapy and therapy line was extracted. Subsequently, a regression analysis was 
used to specifically determine the “time to next treatment (TTNT)”. TTNT is used 
in our model study to reflect the positive correlation of response to therapy and 
disease progression, which has shown to be highly related (2-5). Using TTNT, the 
model can now demonstrate which sequence of therapies in 1st, 2nd and 3rd line 
will total to a possible OS of a patient. Results: We analyzed 13 sequences from 
over 200 theoretical combinations, based on their German approval. Early usage of 
new compounds results in a prolongation of overall survival of at least 6 months, 
compared to the standard therapy with melphalan/prednisone (6), with minimal 
possible OS between 3.98 and 5.06 years. Cost data from Germany were included 
to amount costs of therapy for a complete sequence. For the sequences presented, 
costs range between 69.000 and 135.000 € . The majority of those costs accrue from 
drugs, not from other resources. cOnclusiOns: An important topic of modeling 
approaches is to show both internal and external validity, which is both needed to 
validate the prognoses. The external validation is currently undertaken using data 
from cancer registries and non-interventional studies.
PCN32
The eSTiMaTed Survival of PaTieNTS wiTh double refraCTory ChroNiC 
lyMPhoCyTiC leukaeMia; a reaNalySiS of NiCe Ta202 uSiNg bayeSiaN 
MeThodology To Model obServed daTa
Almond C.1, Stevens J.W.2, Ren K.2, Batty A.1
1BresMed, Sheffield, UK, 2University of Sheffield, Sheffield, UK
Objectives: Standard therapy for chronic lymphocytic leukaemia (CLL) is fludara-
bine, followed by alemtuzumab. Patients resistant to both treatments (double refrac-
tory (DR)-CLL) receive best supportive care (BSC). Ofatumumab is licensed for the 
treatment of DR-CLL, but was not recommended by the National Institute for Health 
and Care Excellence (NICE technology appraisal 202 (TA202)). There is little clinical 
data for BSC in DR-CLL. TA202 identified a single-arm study of ofatumumab and 
an observational study of BSC. Survival for BSC in TA202 was modelled by fitting a 
Weibull distribution to data for ofatumumab non-responders. The effects of ofatu-
mumab were estimated by assuming a proportional hazards model. The objective of 
this study was to investigate the potential sources of survival data for BSC, and the 
impact of the choice of survival distributions used in TA202 on the cost-effectiveness 
of ofatumumab. MethOds: Individual patient-level data was reconstructed from 
Kaplan-Meier curves using a published algorithm. Plausible survivor functions were 
fitted to the data using Markov chain Monte-Carlo simulation. Goodness-of-fit to 
the observed data was assessed using deviance information criterion and the clini-
cal plausibility of extrapolations using subjective opinion. The cost-effectiveness 
model from TA202 was reproduced including alternative survival data. Results: 
A Weibull distribution provided the best fit to the data and was most clinically 
plausible. If proportional hazards were assumed (as in TA202) the incremental cost-
effectiveness ratio (ICER, incremental cost per life year gained) was £52,400, simi-
lar to £49,252 reported in TA202. Relaxing the assumption of proportional hazards 
increased the ICER to £85,618. cOnclusiOns: The best fitting and most clinically 
plausible model was a Weibull distribution, giving results consistent with TA202; 
however both the use of a subgroup of a single arm trial and of data from multiple 
studies has a high level of uncertainty. Relaxing the assumption of proportional 
hazards increased the ICER.
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Objectives: The VELOUR trial demonstrated significant survival benefit for afliber-
cept plus FOLFIRI (5-fluorouracil-leuocovorin-irinotecan) versus FOLFIRI alone in 
mCRC patients previously treated with oxaliplatin. Multivariate analysis identified 
a subset of “better responder” patients who derive sustained benefit with AF, which 
includes patients who did not experience an early relapse directly from adjuvant 
setting (10% of patients included in VELOUR) and with either ECOG PS0 or (PS1 and 
≤ 1 metastatic site). Median OS was significantly improved in AF arm: 16.2 versus 
13.1 months for PF (adjusted HR = 0.73 [95% CI: 0.61–0.86]). Mean survival estimation 
can render a more meaningful estimate for long-term benefit of interventions and 
can be effectively applied to clinical and economic decision support. Our objective 
was to derive mean OS for the “better responders” subgroup in VELOUR. MethOds: 
As survival probability at the end of the follow-up period was 21% in AF vs 8% in PF, 
mean OS was estimated by extrapolating the KM curve using a survival function over 
a 15-year period. Five standard parametric distributions were tested: exponential, 
Weibull, lognormal, loglogistic and Gompertz. Goodness-of-fit of distributions was 
evaluated by Akaike’s Information Criteria (AIC), Bayesian Information Criteria (BIC) 
and graphical methods. Results: Of the 1226 patients enrolled in VELOUR, 404 
Objectives: Off-label use of medications is extremely common especially in 
oncology. The aim of this study is to help update the guidelines and determine 
pharmaceuticals and off-label indications in breast cancer. MethOds: This study 
involved patients (n= 1317) with metastatic breast cancer with tumors that were 
defined as human epidermal growth factor receptor 2, ErbB-2 positive who received 
trastuzumab or other medicine application off-label usage in Turkey. During this 
period using trastuzumab was licenced only for 9 weeks, not for 52 weeks in Turkey. 
A computer search was performed using the TITCK’s ( Turkish Drug and Medical 
Devices Institution) database. The patient base was searched for off-label medi-
cine applications between 1 June 2008 to 1 June 2010. Results: The average age 
were 49.02 ± 10.46. Overall, 85 % of applications were approved in generally 8 or 9 
weeks period. It was found that the Marmara Region had the highest application 
percentage (33.26 %) and then the Central Anatolia Region (27.9 %). Evaluated on 
the base of cities Istanbul, Ankara and Izmir had the most applications with 29.6 
%, 19.2 % and 15.7 % respectively. University hospitals were created the most of 
the applications (81.1%), other applicaitons were from education & research hos-
pitals (10.2 %) and private hospitals ( 5.9 %). Off-label drug usage in breast cancer 
medication, physicians were preferred trastuzumab, trastuzumab+vinoralbin and 
lapatinib. cOnclusiOns: Trastuzumab had the highest percentage in all off-label 
medicine applications for breast cancer usage. On the other hand, 85 % of all tras-
tuzumab off-label usage applications were approved. The reason of 15 % of trastu-
zumab applications is needed to be investigated further.
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Objectives: To assess the patient population with advanced non-small cell lung 
cancer (NSCLC) with EGFR (epidermal growth factor receptor) positive mutation 
in Germany who are eligible for tyrosine-kinase inhibitor (TKI) therapy. An accu-
rate assessment of the relevant patient population provides the basis for budget 
impact analyses in health technology assessments. MethOds: A systematic litera-
ture review was conducted. In addition, data from various cancer registries, cohort 
studies and surveillance studies were analyzed and compared with the findings 
in the literature. Results: In a first step the proportion of patients with NSCLC 
was determined. Data was further differentiated by histologic subgroup (adeno-
carcinoma, large-cell carcinoma, squamous carcinoma and other carcinoma). The 
analysis revealed that the proportion of adenocarcinoma among the group of NSCLC 
has increased in Germany, especially among women from about 40% in 2000 to over 
58% in 2009, in men from 28% to almost 40%, respectively. The proportion of patients 
with locally advanced or metastatic NSCLC (stage IIIb/IV) ranged between 51%-70%. 
The proportion of patients harbouring an EGFR mutation ranged between 5%-17%, 
differing by histologic subgroup, with the highest EGFR mutation rates (9%-26%) 
in patients with adenocarcinoma. The distribution of patients by ECOG (Eastern 
Cooperative Oncology Group) Performance Status (PS) showed that at diagnosis 63%-
92% had an ECOG-PS 0-1. On average, first line therapy was received by over 80% of 
patients, while only 52%-65% underwent second line therapy and third line therapy 
was received by 15%-25% only. cOnclusiOns: By analyzing all available data it is 
possible to provide good estimates of the relevant patient population. Although 
significant advances have been made in reporting and data collection for relevant 
patient subgroups related to NSCLC, there still is a large lack of representative data 
on a national level in Germany.
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Objectives: Prostate cancer (PC) is the most common solid neoplasm in Europe. 
Accurate estimates of prevalence and patient flow through PC states are necessary 
to analyse disease burden and the health economic impact of novel therapies. This 
study presents a dynamic patient progression model (PM) estimating the popula-
tion size of 13 PC clinical states across 8 European countries (EU8; Belgium, France, 
Germany, Italy, The Netherlands, Spain, Sweden, and UK). MethOds: A dynamic 
PM was developed using a 27-year time horizon to estimate the prevalence and 
progression of PC from diagnosis through possible death, using a sequence of 13 
Markov clinical states (5 non-metastatic and 8 metastatic). Incidence data were 
taken from local country registries from 1993 to 2012, and a simple growth model 
was used to forecast incidence rates to 2020 and beyond. PM flow structure, prob-
abilities of prevalence, progression, and mortality per clinical state were determined 
using a Delphi panel of PC experts from the EU8 countries and based on published 
literature and local research. Results: A consensus of expert opinion was reached 
on the clinical states and flow rates of patients with PC in Europe. This resulted in 
a refined PM with new clinical states that represent the current treatment para-
digm for PC. The PM also estimated growth in prevalence and mortality of future 
PC patient populations across 13 different clinical states of PC from 2012 to 2020. 
Five-year prevalence rates from the PM were in agreement with those from the 
GLOBOCAN 2008 project. cOnclusiOns: The PM obtained by consensus of expert 
opinions provided patient prevalence and mortality estimates for 13 distinct PC 
clinical states. The PM and patient flow rates provide a representative simulation 
of the local environment, which can be used to assess PC disease burden, health 
economic impact, and cost of PC care in the EU.
